{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:25:04Z","timestamp":1787682304834,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"UW-Milwaukee's Shimadzu Laboratory"},{"name":"Applied Analytical Chemistry"},{"name":"Milwaukee Institute of Drug Discovery"},{"name":"University of Wisconsin Research Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.neuropharm.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T17:28:16Z","timestamp":1525368496000},"page":"332-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy"],"prefix":"10.1016","volume":"137","author":[{"given":"J.M.","family":"Witkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.D.","family":"Gleason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Poe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Schkeryantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.I.","family":"Alatorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.N.","family":"Siemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.C.","family":"Airey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.R.","family":"Methuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4394-6317","authenticated-orcid":false,"given":"V.V.N.P.B.","family":"Tiruveedhula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Krambis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.05.006_bib1","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2174\/156802611795371350","article-title":"GABAA receptor subtype-selective modulators. I. \u03b12\/\u03b13-selective agonists as non-sedating anxiolytics","volume":"11","author":"Atack","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1124\/jpet.109.158303","article-title":"Reducing abuse liability of GABAA\/benzodiazepine ligands via selective partial agonist efficacy at alpha 1 and alpha2\/3 subtypes","volume":"332","author":"Ator","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/1536867X0900900208","article-title":"The Skillings-Mack test (Friedman test when there are missing data)","volume":"9","author":"Chatfield","year":"2009","journal-title":"STATA J."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2018.05.006_bib6","first-page":"1","article-title":"Benzodiazepines - effects on human performance and behavior","volume":"14","author":"Drummer","year":"2002","journal-title":"Forensic Sci. Rev."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib7","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuropharm.2010.08.011","article-title":"Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure","volume":"59","author":"Fischer","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.05.006_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.brainresbull.2017.03.001","article-title":"Pharmacological and antihyperalgesic properties of the novel \u03b12\/3 preferring GABAA receptor ligand MP-III-024","volume":"131","author":"Fischer","year":"2017","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0165-6147(99)01318-8","article-title":"Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders","volume":"20","author":"Gasior","year":"1999","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.neuropharm.2018.05.006_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4103\/ijmr.IJMR_1051_16","article-title":"Epilepsy: is there hope?","volume":"144","author":"Guerreiro","year":"2016","journal-title":"Indian J. Med. Res."},{"issue":"6","key":"10.1016\/j.neuropharm.2018.05.006_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/WNP.0b013e3181fdf8d3","article-title":"Aberrant neuronal avalanches in cortical tissue removed from juvenile epilepsy patients","volume":"27","author":"Hobbs","year":"2010","journal-title":"J.\u00a0Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1021\/jm990341r","article-title":"Pharmacophore\/receptor models for GABAA\/BzR subtypes (\u03b11\u03b23\u03b32, \u03b15\u03b23\u03b32, and \u03b16\u03b23\u03b32) via a comprehensive ligand-mapping approach","volume":"43","author":"Huang","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.eplepsyres.2016.02.006","article-title":"Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: systematic review and meta-analysis","volume":"122","author":"Jain","year":"2016","journal-title":"Epilepsy Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2018.05.006_bib14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0091-3057(79)90125-4","article-title":"Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors","volume":"11","author":"Klepner","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.neuropharm.2018.05.006_bib15","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1021\/acschemneuro.6b00447","article-title":"Antinociceptive effects of a novel \u03b12\/\u03b13-subtype selective GABAA receptor positive allosteric modulator","volume":"8","author":"Lewter","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib16","first-page":"170","article-title":"An antidepressant-related pharmacological signature for positive allosteric modulators of \u03b12\/3-containing GABAA receptors","volume":"2018","author":"Methuku","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.108.138859","article-title":"NS11394 [3'-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in\u00a0vitro actions, pharmacokinetic properties and in\u00a0vivo anxiolytic Efficacy","volume":"327","author":"Mirza","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.neuropharm.2018.05.006_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","article-title":"Likert scales, levels of measurement and the \"laws\" of statistics","volume":"15","author":"Norman","year":"2010","journal-title":"Adv. Health Sci. Educ. Theory Pract."},{"issue":"23","key":"10.1016\/j.neuropharm.2018.05.006_bib19","doi-asserted-by":"crossref","first-page":"10800","DOI":"10.1021\/acs.jmedchem.6b01332","article-title":"Synthesis and characterization of a novel GABAA receptor ligand, 5-(8-Ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole (KRM-II-81), that combines exceptional drug stability, pharmacokinetics, and anxiolytic efficacy","volume":"59","author":"Poe","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib20","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","author":"Ralvenius","year":"2015","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.neuropharm.2018.05.006_bib21","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1021\/jm801652d","article-title":"Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models","volume":"52","author":"Rivas","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"issue":"3","key":"10.1016\/j.neuropharm.2018.05.006_bib22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1073\/pnas.0405621102","article-title":"Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates","volume":"102","author":"Rowlett","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6755","key":"10.1016\/j.neuropharm.2018.05.006_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2018.05.006_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016","volume":"69","author":"Shih","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1568015054863837","article-title":"Heterogeneity of GABAA receptors: revived interest in the development of subtype-selective drugs","volume":"5","author":"Sieghart","year":"2005","journal-title":"Curr. Med. Chem. Cent. Nerv. Syst. Agents"},{"issue":"11","key":"10.1016\/j.neuropharm.2018.05.006_bib26","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2012.08.003","article-title":"Anxioselective anxiolytics: on a quest for the holy grail","volume":"33","author":"Skolnick","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib27","series-title":"Antiepileptic Drugs","first-page":"85","article-title":"General principles: experimental selection, quantification, and evaluation of anticonvulsants","author":"Swinyard","year":"1989"},{"key":"10.1016\/j.neuropharm.2018.05.006_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pbb.2017.04.009","article-title":"Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for \u03b12\/3-containing GABAA receptors","volume":"157","author":"Witkin","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0269881115620435","article-title":"NS11821, a partial subtype-selective GABAA agonist, elicits selective effects on the central nervous system in randomized controlled trial with healthy subjects","volume":"30","author":"Zuiker","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.05.006_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/jpet.114.212779","article-title":"Perampanel (Fycompa\u00ae), the first FDA-approved antagonist of \u03b1-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid (AMPA) receptors for the treatment of epilepsy: studies in human epileptic brain, non-epileptic brain, and in rodent models","volume":"351","author":"Zwart","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp.Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818302053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T13:31:41Z","timestamp":1561210301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818302053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":30,"alternative-id":["S0028390818302053"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.006","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}